Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) EBITDA (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of EBITDA data on record, last reported at $2.5 million in Q3 2025.

  • For Q3 2025, EBITDA fell 42.06% year-over-year to $2.5 million; the TTM value through Sep 2025 reached $6.7 million, up 139.09%, while the annual FY2024 figure was $3.9 million, 117.73% up from the prior year.
  • EBITDA reached $2.5 million in Q3 2025 per PLX's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $20.4 million in Q2 2023 and bottomed at -$14.3 million in Q4 2023.
  • Average EBITDA over 5 years is -$696368.4, with a median of -$2.4 million recorded in 2024.
  • The widest YoY moves for EBITDA: up 469.68% in 2023, down 472.18% in 2023.
  • A 5-year view of EBITDA shows it stood at $9.0 million in 2021, then plummeted by 127.83% to -$2.5 million in 2022, then plummeted by 472.18% to -$14.3 million in 2023, then soared by 150.5% to $7.2 million in 2024, then tumbled by 65.28% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $2.5 million in Q3 2025, $1.2 million in Q2 2025, and -$4.1 million in Q1 2025.